The utility of ISCOMATRIX™ adjuvant for dose reduction of antigen for vaccines requiring antibody responses

Vaccine

Volumn 25, Issue 14, 2007, Pages 2541-2544

  Boyle, Jeff ^a   Eastman, Donna ^b   Millar, Christine ^a   Camuglia, Sarina ^a   Cox, John ^a   Pearse, Martin ^a   Good, Jeremy ^b   Drane, Debbie ^a  

^a CSL LIMITED   (Australia)

^b VaxGen Inc   (United States)

Author keywords

gp120; HIV; Influenza; ISCOMATRIX adjuvant; Vaccine

Indexed keywords

ALUMINUM HYDROXIDE; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOLOGICAL ADJUVANT; ISCOMATRIX; UNCLASSIFIED DRUG; CHOLESTEROL; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; PHOSPHOLIPID; RECOMBINANT VACCINE; SAPONIN;

ACTIVE IMMUNIZATION; ADJUVANT THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENCY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; NONHUMAN; PRIORITY JOURNAL; VACCINATION; ANIMAL; BLOOD; CHO CELL; CRICETULUS; DOSE RESPONSE; DRUG COMBINATION; GUINEA PIG; HAMSTER; IMMUNOLOGY;

ADJUVANTS, IMMUNOLOGIC; AIDS VACCINES; ANIMALS; CHO CELLS; CHOLESTEROL; CRICETINAE; CRICETULUS; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; DRUG COMBINATIONS; GUINEA PIGS; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; PHOSPHOLIPIDS; SAPONINS; VACCINES, SYNTHETIC;

EID: 33947106966     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2006.12.018     Document Type: Article

References (14)

1. Drane D., and Pearse M. The ISCOMATRIX adjuvant. In: Schijns V.E., and O'Hagan D.T. (Eds). Immunopotentiators in modern vaccines (2006), Elsevier Academic Press, Amsterdam/Boston 191-216
2. + T cell responses in humans. Proc Natl Acad Sci USA 101 (2004) 10697-10702
3. Frazer I.H., Quinn M., Nicklin J.L., Tan J., Perrin L.C., Ng P., et al. Phase 1 study of HPV16-specific immunotherapy with E6E7 fusion protein and ISCOMATRIX adjuvant in women with cervical intraepithelial neoplasia. Vaccine 23 2 (2004) 172-181
4. Sjölander A., Van't Land B., and Lövgren-Bengtsson K. Iscoms containing purified Quillaja saponins upregulate both Th1-like and Th2-like immune responses. Cell Immunol 177 1 (1997) 69-76
5. Graham B.S., Matthews T.J., Belshe R.B., Clements M.L., Dolin R., Wright P.F., et al. Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. The NIAID AIDS Vaccine Clinical Trials Network. J Infect Dis 167 3 (1993) 533-537
6. Morein B., and Lövgren-Bengtsson K. Immunomodulation by iscoms, immune stimulating complexes. Methods 19 1 (1999) 94-102
7. Sjölander A., Drane D., Maraskovsky E., Scheerlinck J.P., Suhrbier A., Tennent J., et al. Immune responses to ISCOM formulations in animal and primate models. Vaccine 19 17-19 (2001) 2661-2665
8. Windon R.G., Chaplin P.J., Beezum L., Coulter A., Cahill R., Kimpton W., et al. Induction of lymphocyte recruitment in the absence of a detectable immune response. Vaccine 19 4-5 (2000) 572-578
9. Watson D.L., Watson N.A., Fossum C., Lövgren K., and Morein B. Interactions between immune-stimulating complexes (ISCOMs) and peritoneal mononuclear leucocytes. Microbiol Immunol 36 (1992) 199-203
10. + T-cell-mediated immunity and protection against NY-ESO-1+ tumors. Clin Cancer Res 10 8 (2004) 2879-2890
11. Kersten G.F.A., and Crommelin D.J.A. Liposomes and ISCOMs. Vaccine 21 9-10 (2003) 915-920
12. Ennis F.A., Cruz J., Jameson J., Klein M., Burt D., and Thipphawong J. Augmentation of human influenza A virus-specified cytotoxic T lymphocyte memory by influenza vaccine and adjuvanted carriers (ISCOMS). Virology 259 2 (1999) 256-261
13. Coulter A., Wong T.Y., Drane D., Bates J., Macfarlan R., and Cox J. Studies on experimental adjuvanted influenza vaccines: comparison of immune stimulating complexes (Iscoms(TM)) and oil- in-water vaccines. Vaccine 16 11/12 (1998) 1243-1253
14. Deliyannis G., Jackson D.C., Dyer W., Bates J., Coulter A., Harling-McNabb L., et al. Immunopotentiation of humoral and cellular responses to inactivated influenza vaccines by two different adjuvants with potential for human use. Vaccine 16 (1998) 2058-2068